The molecular mechanisms underlying the therapeutic resistance of cancer stem cells

Archives of Pharmacal Research

Volumn 38, Issue 3, 2015, Pages 389-401

  Kim, Jun Kyum ^a   Jeon, Hee Young ^a   Kim, Hyunggee ^a  

^a Korea University   (South Korea)

Author keywords

Cancer stem cells; Chemo resistance; Radio resistance; Tumor microenvironment; Tumor recurrence

Indexed keywords

ABC TRANSPORTER A1; BETA CATENIN; BREAST CANCER RESISTANCE PROTEIN; CHEMOKINE RECEPTOR CXCR4; FLICE INHIBITORY PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN; NOTCH RECEPTOR; POLYCOMB GROUP PROTEIN; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE; SONIC HEDGEHOG PROTEIN; ANTINEOPLASTIC AGENT;

APOPTOSIS; CANCER INHIBITION; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STEM CELL; DNA DAMAGE; DNA DAMAGE CHECKPOINT; DNA REPAIR; DRUG RESISTANCE; HUMAN; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RADIOSENSITIVITY; REVIEW; TARGET CELL; TUMOR MICROENVIRONMENT; WNT SIGNALING PATHWAY; DISEASE COURSE; METABOLISM; NEOPLASMS; PATHOLOGY; RADIATION DOSE; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; NEOPLASTIC STEM CELLS; RADIATION TOLERANCE;

EID: 84925505862     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-014-0531-1     Document Type: Review

References (131)

1. Abdullah, L.N., and E.K. Chow. 2013. Mechanisms of chemoresistance in cancer stem cells. Clinical and Translational Medicine 2: 3.
2. Agarwal, J.R., and W. Matsui. 2010. Multiple myeloma: A paradigm for translation of the cancer stem cell hypothesis. Anticancer Agents in Medical Chemistry 10: 116-120.
3. Ailles, L.E., and I.L. Weissman. 2007. Cancer stem cells in solid tumors. Current Opinion in Biotechnology 18: 460-466.
4. Bao, S., Q. Wu, R.E. Mclendon, Y. Hao, Q. Shi, A.B. Hjelmeland, M.W. Dewhirst, D.D. Bigner, and J.N. Rich. 2006. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444: 756-760.
5. Bar, E.E., A. Chaudhry, A. Lin, X. Fan, K. Schreck, W. Matsui, S. Piccirillo, A.L. Vescovi, F. Dimeco, A. Olivi, and C.G. Eberhart. 2007. Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells 25: 2524-2533.
6. Bartucci, M., S. Svensson, P. Romania, R. Dattilo, M. Patrizii, M. Signore, S. Navarra, F. Lotti, M. Biffoni, E. Pilozzi, E. Duranti, S. Martinelli, C. Rinaldo, A. Zeuner, M. Maugeri-Sacca, A. Eramo, and R. De Maria. 2012. Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy. Cell Death and Differentiation 19: 768-778.
7. Blanpain, C., M. Mohrin, P.A. Sotiropoulou, and E. Passegue. 2011. DNA-damage response in tissue-specific and cancer stem cells. Cell Stem Cell 8: 16-29.
8. Bleau, A.M., D. Hambardzumyan, T. Ozawa, E.I. Fomchenko, J.T. Huse, C.W. Brennan, and E.C. Holland. 2009. PTEN/PI3 K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 4: 226-235.
9. Blotta, S., J. Jakubikova, T. Calimeri, A.M. Roccaro, N. Amodio, A.K. Azab, U. Foresta, C.S. Mitsiades, M. Rossi, K. Todoerti, S. Molica, F. Morabito, A. Neri, P. Tagliaferri, P. Tassone, K.C. Anderson, and N.C. Munshi. 2012. Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma. Blood 120: 5002-5013.
10. Borovski, T., E.M.F. De Sousa, L. Vermeulen, and J.P. Medema. 2011. Cancer stem cell niche: The place to be. Cancer Research 71: 634-639.
11. Bourguignon, L.Y., G. Wong, C. Earle, and L. Chen. 2012. Hyaluronan-CD44v3 interaction with Oct4-Sox2-Nanog promotes miR-302 expression leading to self-renewal, clonal formation, and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma. The Journal of biological chemistry 287: 32800-32824.
12. Bouwman, P., and J. Jonkers. 2012. The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. Nature Reviews Cancer 12: 587-598.
13. Boyer, M.J., and T. Cheng. 2008. The CDK inhibitors: Potential targets for therapeutic stem cell manipulations? Gene Therapy 15: 117-125.
14. Burger, J.A., and A. Peled. 2009. CXCR4 antagonists: Targeting the microenvironment in leukemia and other cancers. Leukemia 23: 43-52.
15. Burkhardt, J.K., C.P. Hofstetter, A. Santillan, B.J. Shin, C.P. Foley, D.J. Ballon, Y. Pierre Gobin, and J.A. Boockvar. 2012. Orthotopic glioblastoma stem-like cell xenograft model in mice to evaluate intra-arterial delivery of bevacizumab: From bedside to bench. Journal of Clinical Neuroscience 19: 1568-1572.
16. Cabarcas, S.M., L.A. Mathews, and W.L. Farrar. 2011. The cancer stem cell niche-there goes the neighborhood? International Journal of Cancer 129: 2315-2327.
17. Calabrese, C., H. Poppleton, M. Kocak, T.L. Hogg, C. Fuller, B. Hamner, E.Y. Oh, M.W. Gaber, D. Finklestein, M. Allen, A. Frank, I.T. Bayazitov, S.S. Zakharenko, A. Gajjar, A. Davidoff, and R.J. Gilbertson. 2007. A perivascular niche for brain tumor stem cells. Cancer Cell 11: 69-82.
18. Calcagno, A.M., C.D. Salcido, J.P. Gillet, C.P. Wu, J.M. Fostel, M.D. Mumau, M.M. Gottesman, L. Varticovski, and S.V. Ambudkar. 2010. Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics. Journal of the National Cancer Institute 102: 1637-1652.
19. Chau, W.K., C.K. Ip, A.S. Mak, H.C. Lai, and A.S. Wong. 2013. c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/beta-catenin-ATP-binding cassette G2 signaling. Oncogene 32: 2767-2781.
20. Chen, L., S.M. Park, A.V. Tumanov, A. Hau, K. Sawada, C. Feig, J.R. Turner, Y.X. Fu, I.L. Romero, E. Lengyel, and M.E. Peter. 2010. CD95 promotes tumour growth. Nature 465: 492-496.
21. Cimprich, K.A., and D. Cortez. 2008. ATR: An essential regulator of genome integrity. Nature Reviews Molecular Cell Biology 9: 616-627.
22. Croker, A.K., and A.L. Allan. 2008. Cancer stem cells: Implications for the progression and treatment of metastatic disease. Journal of Cellular and Molecular Medicine 12: 374-390.
23. Dai, Y., and S. Grant. 2010. New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clinical Cancer Research 16: 376-383.
24. Deangelo, D., R. Stone, L. Silverman, W. Stock, E. Attar, I. Fearen, A. Dallob, C. Matthews, J. Stone, and S. Freedman. 2006. A phase I clinical trial of the notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other leukemias. Journal of Clinical Oncology 24: 6585.
25. Desai, A., B. Webb, and S.L. Gerson. 2014. CD133+ cells contribute to radioresistance via altered regulation of DNA repair genes in human lung cancer cells. Radiotherapy and Oncology 110: 538-545.
26. Dick, J.E. 2008. Stem cell concepts renew cancer research. Blood 112: 4793-4807.
27. Diehn, M., R.W. Cho, N.A. Lobo, T. Kalisky, M.J. Dorie, A.N. Kulp, D. Qian, J.S. Lam, L.E. Ailles, M. Wong, B. Joshua, M.J. Kaplan, I. Wapnir, F.M. Dirbas, G. Somlo, C. Garberoglio, B. Paz, J. Shen, S.K. Lau, S.R. Quake, J.M. Brown, I.L. Weissman, and M.F. Clarke. 2009. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 458: 780-783.
28. Domingo-Domenech, J., S.J. Vidal, V. Rodriguez-Bravo, M. Castillo-Martin, S.A. Quinn, R. Rodriguez-Barrueco, D.M. Bonal, E. Charytonowicz, N. Gladoun, J. De La Iglesia-Vicente, D.P. Petrylak, M.C. Benson, J.M. Silva, and C. Cordon-Cardo. 2012. Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells. Cancer Cell 22: 373-388.
29. Dutton, A., L.S. Young, and P.G. Murray. 2006. The role of cellular FLICE inhibitory protein (c-FLIP) in the pathogenesis and treatment of cancer. Expert Opinion on Therapeutic Targets 10: 27-35.
30. Emami, K.H., C. Nguyen, H. Ma, D.H. Kim, K.W. Jeong, M. Eguchi, R.T. Moon, J.L. Teo, H.Y. Kim, S.H. Moon, J.R. Ha, and M. Kahn. 2004. A small molecule inhibitor of beta-catenin/CREB-binding protein transcription [corrected]. Proceedings of the National Academy of Sciences of United States of America 101: 12682-12687.
31. Feldmann, G., V. Fendrich, K. Mcgovern, D. Bedja, S. Bisht, H. Alvarez, J.B. Koorstra, N. Habbe, C. Karikari, M. Mullendore, K.L. Gabrielson, R. Sharma, W. Matsui, and A. Maitra. 2008. An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer. Molecular Cancer Therapeutics 7: 2725-2735.
32. Fletcher, J.I., M. Haber, M.J. Henderson, and M.D. Norris. 2010. ABC transporters in cancer: More than just drug efflux pumps. Nature Reviews Cancer 10: 147-156.
33. Fujii, N., L. You, Z. Xu, K. Uematsu, J. Shan, B. He, I. Mikami, L.R. Edmondson, G. Neale, J. Zheng, R.K. Guy, and D.M. Jablons. 2007. An antagonist of dishevelled protein-protein interaction suppresses beta-catenin-dependent tumor cell growth. Cancer Research 67: 573-579.
34. Fulda, S. 2013. Regulation of apoptosis pathways in cancer stem cells. Cancer Letters 338: 168-173.
35. Fulda, S., and S. Pervaiz. 2010. Apoptosis signaling in cancer stem cells. The Intrnational Journal of Biochemistry & Cell Biology 42: 31-38.
36. Garcia-Barros, M., F. Paris, C. Cordon-Cardo, D. Lyden, S. Rafii, A. Haimovitz-Friedman, Z. Fuks, and R. Kolesnick. 2003. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300: 1155-1159.
37. Gelmini, S., M. Mangoni, M. Serio, P. Romagnani, and E. Lazzeri. 2008. The critical role of SDF-1/CXCR4 axis in cancer and cancer stem cells metastasis. Journal of Endocrinological Investigation 31: 809-819.
38. Ghotra, V.P., J.C. Puigvert, and E.H. Danen. 2009. The cancer stem cell microenvironment and anti-cancer therapy. International Journal of Radiation Biology 85: 955-962.
39. Gieni, R.S., I.H. Ismail, S. Campbell, and M.J. Hendzel. 2011. Polycomb group proteins in the DNA damage response: A link between radiation resistance and "stemness". Cell Cycle 10: 883-894.
40. Gilbert, C.A., M.C. Daou, R.P. Moser, and A.H. Ross. 2010. Gamma-secretase inhibitors enhance temozolomide treatment of human gliomas by inhibiting neurosphere repopulation and xenograft recurrence. Cancer Research 70: 6870-6879.
41. Gilbert, L.A., and M.T. Hemann. 2010. DNA damage-mediated induction of a chemoresistant niche. Cell 143: 355-366.
42. Ginjala, V., K. Nacerddine, A. Kulkarni, J. Oza, S.J. Hill, M. Yao, E. Citterio, M. Van Lohuizen, and S. Ganesan. 2011. BMI1 is recruited to DNA breaks and contributes to DNA damage-induced H2A ubiquitination and repair. Molecular and Cellular Biology 31: 1972-1982.
43. Hanahan, D., and R.A. Weinberg. 2011. Hallmarks of cancer: The next generation. Cell 144: 646-674.
44. Haraguchi, N., H. Ishii, K. Mimori, F. Tanaka, M. Ohkuma, H.M. Kim, H. Akita, D. Takiuchi, H. Hatano, H. Nagano, G.F. Barnard, Y. Doki, and M. Mori. 2010. CD13 is a therapeutic target in human liver cancer stem cells. Journal of Clinical Investigation 120: 3326-3339.
45. Harrison, H., G. Farnie, S.J. Howell, R.E. Rock, S. Stylianou, K.R. Brennan, N.J. Bundred, and R.B. Clarke. 2010. Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. Cancer Research 70: 709-718.
46. Hoey, T., W.C. Yen, F. Axelrod, J. Basi, L. Donigian, S. Dylla, M. Fitch-Bruhns, S. Lazetic, I.K. Park, A. Sato, S. Satyal, X. Wang, M.F. Clarke, J. Lewicki, and A. Gurney. 2009. DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell 5: 168-177.
47. Holohan, C., S. Van Schaeybroeck, D.B. Longley, and P.G. Johnston. 2013. Cancer drug resistance: An evolving paradigm. Nature Reviews Cancer 13: 714-726.
48. Hong, Z., J. Jiang, L. Lan, S. Nakajima, S. Kanno, H. Koseki, and A. Yasui. 2008. A polycomb group protein, PHF1, is involved in the response to DNA double-strand breaks in human cell. Nucleic Acids Research 36: 2939-2947.
49. Ishimoto, T., O. Nagano, T. Yae, M. Tamada, T. Motohara, H. Oshima, M. Oshima, T. Ikeda, R. Asaba, H. Yagi, T. Masuko, T. Shimizu, T. Ishikawa, K. Kai, E. Takahashi, Y. Imamura, Y. Baba, M. Ohmura, M. Suematsu, H. Baba, and H. Saya. 2011. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell 19: 387-400.
50. Jagani, Z., M. Dorsch, and M. Warmuth. 2010. Hedgehog pathway activation in chronic myeloid leukemia. Cell Cycle 9: 3449-3456.
51. Jiang, X., Y. Zhao, C. Smith, M. Gasparetto, A. Turhan, A. Eaves, and C. Eaves. 2007. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia 21: 926-935.
52. Kendziorra, E., K. Ahlborn, M. Spitzner, M. Rave-Frank, G. Emons, J. Gaedcke, F. Kramer, H.A. Wolff, H. Becker, T. Beissbarth, R. Ebner, B.M. Ghadimi, T. Pukrop, T. Ried, and M. Grade. 2011. Silencing of the Wnt transcription factor TCF4 sensitizes colorectal cancer cells to (chemo-) radiotherapy. Carcinogenesis 32: 1824-1831.
53. Kim, H.M., N. Haraguchi, H. Ishii, M. Ohkuma, M. Okano, K. Mimori, H. Eguchi, H. Yamamoto, H. Nagano, M. Sekimoto, Y. Doki, and M. Mori. 2012. Increased CD13 expression reduces reactive oxygen species, promoting survival of liver cancer stem cells via an epithelial-mesenchymal transition-like phenomenon. Annals of Surgical Oncology 19(Suppl 3): S539-S548.
54. Kioi, M., H. Vogel, G. Schultz, R.M. Hoffman, G.R. Harsh, and J.M. Brown. 2010. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. Journal of Clinical Investigation 120: 694-705.
55. Konopleva, M., Y. Tabe, Z. Zeng, and M. Andreeff. 2009. Therapeutic targeting of microenvironmental interactions in leukemia: Mechanisms and approaches. Drug Resistance Updates 12: 103-113.
56. Korkaya, H., A. Paulson, E. Charafe-Jauffret, C. Ginestier, M. Brown, J. Dutcher, S.G. Clouthier, and M.S. Wicha. 2009. Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling. PLoS Biology 7: e1000121.
57. Kruyt, F.A., and J.J. Schuringa. 2010. Apoptosis and cancer stem cells: Implications for apoptosis targeted therapy. Biochemical Pharmacology 80: 423-430.
58. Lagadec, C., E. Vlashi, Y. Alhiyari, T.M. Phillips, M. Bochkur Dratver, and F. Pajonk. 2013. Radiation-induced notch signaling in breast cancer stem cells. International Journal of Radiation Oncology Biology Physics 87: 609-618.
59. Lagadec, C., E. Vlashi, L. Della Donna, C. Dekmezian, and F. Pajonk. 2012. Radiation-induced reprogramming of breast cancer cells. Stem Cells 30: 833-844.
60. Lapidot, T., C. Sirard, J. Vormoor, B. Murdoch, T. Hoang, J. Caceres-Cortes, M. Minden, B. Paterson, M.A. Caligiuri, and J.E. Dick. 1994. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367: 645-648.
61. Lee, S.H., H.S. Hong, Z.X. Liu, R.H. Kim, M.K. Kang, N.H. Park, and K.H. Shin. 2012. TNFalpha enhances cancer stem cell-like phenotype via Notch-Hes1 activation in oral squamous cell carcinoma cells. Biochemical Biophysical Research Communications 424: 58-64.
62. Lemke, J., S. Von Karstedt, J. Zinngrebe, and H. Walczak. 2014. Getting TRAIL back on track for cancer therapy. Cell Death and Differentiation 21: 1350-1364.
63. List, A.F., K.J. Kopecky, C.L. Willman, D.R. Head, D.L. Persons, M.L. Slovak, R. Dorr, C. Karanes, H.E. Hynes, J.H. Doroshow, M. Shurafa, and F.R. Appelbaum. 2001. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: A Southwest Oncology Group study. Blood 98: 3212-3220.
64. Liu, C., Z. Li, L. Bi, K. Li, B. Zhou, C. Xu, J. Huang, and K. Xu. 2014. NOTCH1 signaling promotes chemoresistance via regulating ABCC1 expression in prostate cancer stem cells. Molecular and Cellular Biochemistry 393: 265-270.
65. Liu, G., X. Yuan, Z. Zeng, P. Tunici, H. Ng, I.R. Abdulkadir, L. Lu, D. Irvin, K.L. Black, and J.S. Yu. 2006a. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Molecular Cancer 5: 67-79.
66. Liu, S., G. Dontu, I.D. Mantle, S. Patel, N.S. Ahn, K.W. Jackson, P. Suri, and M.S. Wicha. 2006b. Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Research 66: 6063-6071.
67. Lorusso, P., C. Rudin, M. Borad, L. Vernillet, W. Darbonne, H. Mackey, J. Dimartino, F. De Sauvage, J. Low, and D. Von Hoff. 2008. A first-in-human, first-in-class, phase (ph) I study of systemic Hedgehog (Hh) pathway antagonist, GDC-0449, in patients (pts) with advanced solid tumors. Journal of Clinical Oncology 26: 3516.
68. Lowe, S.W., E. Cepero, and G. Evan. 2004. Intrinsic tumour suppression. Nature 432: 307-315.
69. Lu, J., X. Ye, F. Fan, L. Xia, R. Bhattacharya, S. Bellister, F. Tozzi, E. Sceusi, Y. Zhou, I. Tachibana, D.M. Maru, D.H. Hawke, J. Rak, S.A. Mani, P. Zweidler-Mckay, and L.M. Ellis. 2013. Endothelial cells promote the colorectal cancer stem cell phenotype through a soluble form of Jagged-1. Cancer Cell 23: 171-185.
70. Madjd, Z., A.Z. Mehrjerdi, A.M. Sharifi, S. Molanaei, S.Z. Shahzadi, and M. Asadi-Lari. 2009. CD44+ cancer cells express higher levels of the anti-apoptotic protein Bcl-2 in breast tumours. Cancer Immunity 9: 4.
71. Magee, J.A., E. Piskounova, and S.J. Morrison. 2012. Cancer stem cells: Impact, heterogeneity, and uncertainty. Cancer Cell 21: 283-296.
72. Mannino, M., and A.J. Chalmers. 2011. Radioresistance of glioma stem cells: Intrinsic characteristic or property of the 'microenvironment-stem cell unit'? Molecular Oncology 5: 374-386.
73. Masunaga, S., K. Ono, and M. Abe. 1991. A method for the selective measurement of the radiosensitivity of quiescent cells in solid tumors-combination of immunofluorescence staining to BrdU and micronucleus assay. Radiation Research 125: 243-247.
74. Maugeri-Sacca, M., M. Bartucci, and R. De Maria. 2012. DNA damage repair pathways in cancer stem cells. Molecular Cancer Therapeutics 11: 1627-1636.
75. Mcauliffe, S.M., S.L. Morgan, G.A. Wyant, L.T. Tran, K.W. Muto, Y.S. Chen, K.T. Chin, J.C. Partridge, B.B. Poole, K.H. Cheng, J. Daggett Jr, K. Cullen, E. Kantoff, K. Hasselbatt, J. Berkowitz, M.G. Muto, R.S. Berkowitz, J.C. Aster, U.A. Matulonis, and D.M. Dinulescu. 2012. Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy. Proceedings of the National Academy of Sciences of United States of America 109: E2939-E2948.
76. Mcvey, M., and S.E. Lee. 2008. MMEJ repair of double-strand breaks (director's cut): Deleted sequences and alternative endings. Trends in Genetics 24: 529-538.
77. Minderman, H., K.L. O'loughlin, L. Pendyala, and M.R. Baer. 2004. VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Clinical Cancer Research 10: 1826-1834.
78. Moore, N., and S. Lyle. 2011. Quiescent, slow-cycling stem cell populations in cancer: A review of the evidence and discussion of significance. Journal of Oncology 2011: 396076.
79. Narita, Y. 2013. Drug review: Safety and efficacy of bevacizumab for glioblastoma and other brain tumors. Japanese Journal of Clinical Oncology 43: 587-595.
80. Nooter, K., G. Brutel De La Riviere, M.P. Look, K.E. Van Wingerden, S.C. Henzen-Logmans, R.J. Scheper, M.J. Flens, J.G. Klijn, G. Stoter, and J.A. Foekens. 1997. The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancer. British Journal of Cancer 76: 486-493.
81. O'brien, C.A., A. Kreso, and C.H. Jamieson. 2010. Cancer stem cells and self-renewal. Clinical Cancer Research 16: 3113-3120.
82. Orimo, A., P.B. Gupta, D.C. Sgroi, F. Arenzana-Seisdedos, T. Delaunay, R. Naeem, V.J. Carey, A.L. Richardson, and R.A. Weinberg. 2005. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121: 335-348.
83. Patil, Y., T. Sadhukha, L. Ma, and J. Panyam. 2009. Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. Journal of Controlled Release 136: 21-29.
84. Pawlik, T.M., and K. Keyomarsi. 2004. Role of cell cycle in mediating sensitivity to radiotherapy. International Journal of Radiation Oncology Biology Physics 59: 928-942.
85. Phillips, T.M., W.H. Mcbride, and F. Pajonk. 2006. The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. Journal of the National Cancer Institute 98: 1777-1785.
86. Piccin, D., and C.M. Morshead. 2011. Wnt signaling regulates symmetry of division of neural stem cells in the adult brain and in response to injury. Stem Cells 29: 528-538.
87. Qiu, Z.K., D. Shen, Y.S. Chen, Q.Y. Yang, C.C. Guo, B.H. Feng, and Z.P. Chen. 2014. Enhanced MGMT expression contributes to temozolomide resistance in glioma stem-like cells. Chinese Journal of Cancer 33: 115-122.
88. Ranganathan, P., K.L. Weaver, and A.J. Capobianco. 2011. Notch signalling in solid tumours: A little bit of everything but not all the time. Nature Reviews Cancer 11: 338-351.
89. Rao, Y., R. Li, and D. Zhang. 2013. A drug from poison: How the therapeutic effect of arsenic trioxide on acute promyelocytic leukemia was discovered. Science China Life Sciences 56: 495-502.
90. Rath, P.C., and B.B. Aggarwal. 1999. TNF-induced signaling in apoptosis. Journal of Clinical Immunology 19: 350-364.
91. Real, P.J., V. Tosello, T. Palomero, M. Castillo, E. Hernando, E. De Stanchina, M.L. Sulis, K. Barnes, C. Sawai, I. Homminga, J. Meijerink, I. Aifantis, G. Basso, C. Cordon-Cardo, W. Ai, and A. Ferrando. 2009. Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nature Medicine 15: 50-58.
92. Reinhardt, H.C., and M.B. Yaffe. 2009. Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2. Current Opinion in Cell Biology 21: 245-255.
93. Reya, T., S.J. Morrison, M.F. Clarke, and I.L. Weissman. 2001. Stem cells, cancer, and cancer stem cells. Nature 414: 105-111.
94. Rich, J.N. 2007. Cancer stem cells in radiation resistance. Cancer Research 67: 8980-8984.
95. Rizzo, S., J.M. Hersey, P. Mellor, W. Dai, A. Santos-Silva, D. Liber, L. Luk, I. Titley, C.P. Carden, G. Box, D.L. Hudson, S.B. Kaye, and R. Brown. 2011. Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2. Molecular Cancer Therapeutics 10: 325-335.
96. Rouleau, M., D. Mcdonald, P. Gagne, M.E. Ouellet, A. Droit, J.M. Hunter, S. Dutertre, C. Prigent, M.J. Hendzel, and G.G. Poirier. 2007. PARP-3 associates with polycomb group bodies and with components of the DNA damage repair machinery. Journal of Cellular Biochemistry 100: 385-401.
97. Salvesen, G.S., and C.S. Duckett. 2002. IAP proteins: Blocking the road to death's door. Nature Reviews Molecular Cell Biology 3: 401-410.
98. Schatton, T., N.Y. Frank, and M.H. Frank. 2009. Identification and targeting of cancer stem cells. BioEssays 31: 1038-1049.
99. Schatton, T., G.F. Murphy, N.Y. Frank, K. Yamaura, A.M. Waaga-Gasser, M. Gasser, Q. Zhan, S. Jordan, L.M. Duncan, C. Weishaupt, R.C. Fuhlbrigge, T.S. Kupper, M.H. Sayegh, and M.H. Frank. 2008. Identification of cells initiating human melanomas. Nature 451: 345-349.
100. Shan, J., D.L. Shi, J. Wang, and J. Zheng. 2005. Identification of a specific inhibitor of the dishevelled PDZ domain. Biochemistry 44: 15495-15503.
101. Shi, X., Y. Zhang, J. Zheng, and J. Pan. 2012. Reactive oxygen species in cancer stem cells. Antioxidants & Redox Signaling 16: 1215-1228.
102. Shiloh, Y. 2001. ATM and ATR: Networking cellular responses to DNA damage. Current Opinion in Genetics & Development 11: 71-77.
103. Song, Z., W. Yue, B. Wei, N. Wang, T. Li, L. Guan, S. Shi, Q. Zeng, X. Pei, and L. Chen. 2011. Sonic hedgehog pathway is essential for maintenance of cancer stem-like cells in human gastric cancer. PLoS One 6: e17687.
104. Storci, G., P. Sansone, S. Mari, G. D'uva, S. Tavolari, T. Guarnieri, M. Taffurelli, C. Ceccarelli, D. Santini, P. Chieco, K.B. Marcu, and M. Bonafe. 2010. TNFalpha up-regulates SLUG via the NF-kappaB/HIF1alpha axis, which imparts breast cancer cells with a stem cell-like phenotype. Journal of Cellular Physiology 225: 682-691.
105. Sun, L., S.M. Cabarcas, and W.L. Farrar. 2011. Radioresistance and cancer stem cells: Survival of the fittest. Journal of Carcinogenesis & Mutagenesis. doi: 10.4172/2157-2518.S1-004.
106. Tagscherer, K.E., A. Fassl, B. Campos, M. Farhadi, A. Kraemer, B.C. Bock, S. Macher-Goeppinger, B. Radlwimmer, O.D. Wiestler, C. Herold-Mende, and W. Roth. 2008. Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins. Oncogene 27: 6646-6656.
107. Taipale, J., J.K. Chen, M.K. Cooper, B. Wang, R.K. Mann, L. Milenkovic, M.P. Scott, and P.A. Beachy. 2000. Effects of oncogenic mutations in smoothened and Patched can be reversed by cyclopamine. Nature 406: 1005-1009.
108. Takebe, N., P.J. Harris, R.Q. Warren, and S.P. Ivy. 2011. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nature Reviews Clinical Oncology 8: 97-106.
109. Tang, D.G. 2012. Understanding cancer stem cell heterogeneity and plasticity. Cell Research 22: 457-472.
110. Trachootham, D., J. Alexandre, and P. Huang. 2009. Targeting cancer cells by ROS-mediated mechanisms: A radical therapeutic approach? Nature Reviews Drug Discovery 8: 579-591.
111. Trautmann, F., M. Cojoc, I. Kurth, N. Melin, L.C. Bouchez, A. Dubrovska, and C. Peitzsch. 2014. CXCR4 as biomarker for radioresistant cancer stem cells. International Journal of Radiation Biology 90: 687-699.
112. Triller, N., P. Korosec, I. Kern, M. Kosnik, and A. Debeljak. 2006. Multidrug resistance in small cell lung cancer: Expression of P-glycoprotein, multidrug resistance protein 1 and lung resistance protein in chemo-naive patients and in relapsed disease. Lung Cancer 54: 235-240.
113. Van Houdt, W.J., B.L. Emmink, T.V. Pham, S.R. Piersma, A. Verheem, R.G. Vries, S.A. Fratantoni, A. Pronk, H. Clevers, C.R. Jimenez, and O. Kranenburg. 2011. Comparative proteomics of colon cancer stem cells and differentiated tumor cells identifies BIRC6 as a potential therapeutic target. Molecular & Cellular Proteomics 10: M111 011353.
114. Vangipuram, S.D., S.A. Buck, and W.D. Lyman. 2012. Wnt pathway activity confers chemoresistance to cancer stem-like cells in a neuroblastoma cell line. Tumour Biology 33: 2173-2183.
115. Varnat, F., A. Duquet, M. Malerba, M. Zbinden, C. Mas, P. Gervaz, I. Ruiz, and A. Altaba. 2009. Human colon cancer epithelial cells harbour active HEDGEHOG-GLI signalling that is essential for tumour growth, recurrence, metastasis and stem cell survival and expansion. EMBO Molecular Medicine 1: 338-351.
116. Venkatesha, V.A., L.A. Parsels, J.D. Parsels, L. Zhao, S.D. Zabludoff, D.M. Simeone, J. Maybaum, T.S. Lawrence, and M.A. Morgan. 2012. Sensitization of pancreatic cancer stem cells to gemcitabine by Chk1 inhibition. Neoplasia 14: 519-525.
117. Verga Falzacappa, M.V., C. Ronchini, L.B. Reavie, and P.G. Pelicci. 2012. Regulation of self-renewal in normal and cancer stem cells. The FEBS Journal 279: 3559-3572.
118. Vesuna, F., A. Lisok, B. Kimble, and V. Raman. 2009. Twist modulates breast cancer stem cells by transcriptional regulation of CD24 expression. Neoplasia 11: 1318-1328.
119. Vissers, J.H., M. Van Lohuizen, and E. Citterio. 2012. The emerging role of Polycomb repressors in the response to DNA damage. Journal of Cell Science 125: 3939-3948.
120. Von Hoff, D.D., P.M. Lorusso, C.M. Rudin, J.C. Reddy, R.L. Yauch, R. Tibes, G.J. Weiss, M.J. Borad, C.L. Hann, J.R. Brahmer, H.M. Mackey, B.L. Lum, W.C. Darbonne, J.C. Marsters Jr, F.J. De Sauvage, and J.A. Low. 2009. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. The New England Journal of Medicine 361: 1164-1172.
121. Wang, X., Z. Ma, Z. Xiao, H. Liu, Z. Dou, X. Feng, and H. Shi. 2012. Chk1 knockdown confers radiosensitization in prostate cancer stem cells. Oncology Reports 28: 2247-2254.
122. Wang, Z., N. Wang, W. Li, P. Liu, Q. Chen, H. Situ, S. Zhong, L. Guo, Y. Lin, J. Shen, and J. Chen. 2014. Caveolin-1 mediates chemoresistance in breast cancer stem cells via beta-catenin/ABCG2 signaling pathway. Carcinogenesis 35: 2346-2356.
123. Ward, R.J., L. Lee, K. Graham, T. Satkunendran, K. Yoshikawa, E. Ling, L. Harper, R. Austin, E. Nieuwenhuis, I.D. Clarke, C.C. Hui, and P.B. Dirks. 2009. Multipotent CD15+ cancer stem cells in patched-1-deficient mouse medulloblastoma. Cancer Research 69: 4682-4690.
124. Wilson, B.J., K.R. Saab, J. Ma, T. Schatton, P. Putz, Q. Zhan, G.F. Murphy, M. Gasser, A.M. Waaga-Gasser, N.Y. Frank, and M.H. Frank. 2014. ABCB5 maintains melanoma-initiating cells through a proinflammatory cytokine signaling circuit. Cancer Research 74: 4196-4207.
125. Withers, H.R., J.M. Taylor, and B. Maciejewski. 1988. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncologica 27: 131-146.
126. Yang, W., H.X. Yan, L. Chen, Q. Liu, Y.Q. He, L.X. Yu, S.H. Zhang, D.D. Huang, L. Tang, X.N. Kong, C. Chen, S.Q. Liu, M.C. Wu, and H.Y. Wang. 2008. Wnt/beta-catenin signaling contributes to activation of normal and tumorigenic liver progenitor cells. Cancer Research 68: 4287-4295.
127. Yeung, J., M.T. Esposito, A. Gandillet, B.B. Zeisig, E. Griessinger, D. Bonnet, and C.W. So. 2010. beta-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells. Cancer Cell 18: 606-618.
128. Yin, H., and J. Glass. 2011. The phenotypic radiation resistance of CD44+/CD24(-or low) breast cancer cells is mediated through the enhanced activation of ATM signaling. PLoS One 6: e24080.
129. Zabludoff, S.D., C. Deng, M.R. Grondine, A.M. Sheehy, S. Ashwell, B.L. Caleb, S. Green, H.R. Haye, C.L. Horn, J.W. Janetka, D. Liu, E. Mouchet, S. Ready, J.L. Rosenthal, C. Queva, G.K. Schwartz, K.J. Taylor, A.N. Tse, G.E. Walker, and A.M. White. 2008. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Molecular Cancer Therapeutics 7: 2955-2966.
130. Zhang, G., Z. Wang, W. Luo, H. Jiao, J. Wu, and C. Jiang. 2013. Expression of potential cancer stem cell marker ABCG2 is associated with malignant behaviors of hepatocellular carcinoma. Gastroenterology Research and Practice 2013: 782581.
131. Zhao, C., A. Chen, C.H. Jamieson, M. Fereshteh, A. Abrahamsson, J. Blum, H.Y. Kwon, J. Kim, J.P. Chute, D. Rizzieri, M. Munchhof, T. Vanarsdale, P.A. Beachy, and T. Reya. 2009. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 458: 776-779.